Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Bristol Myers Squibb $4.5 billion notes offering
The investment-grade offering comprised four tranches
Alector $125 million at-the-market offering
The common stock is listed on the Nasdaq Global Select Market
NeuroPace $50 million at-the-market offering
The stock is listed on the Nasdaq Global Market
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
GSK exclusive license agreement for HS-20089 with Hansoh Pharma
We advised GSK on the transaction
GSK collaboration extension and new data licensing agreement with 23andMe
We advised GSK on the transaction
IDEAYA Biosciences $143.8 million equity offering
The common stock is listed on the Nasdaq Global Select Market
Aligos Therapeutics $92 million private placement
The PIPE included common stock and warrants
Pharmaceuticals company response to activist approach
We advised the company on an activist approach
Roche $7.1 billion acquisition of Telavant and rights to RVT 3101 from Roivant
We are advising Roche on the acquisition